Rosuvastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Because of their excellent tolerability and their positive impact on lipid parameters, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have become the drugs of first choice for many patients with dyslipidemia. Rosuvastatin is an investigational statin in the U.S. with a number of favorable characteristics, which include low lipophilicity, high hepatocyte selectivity, minimal metabolism, and a low propensity for cytochrome P450 drug interactions. Rosuvastatin has been studied at doses ranging from 1 to 80 mg. In comparative clinical trials, rosuvastatin given at 5 to 10 mg/day reduced low-density lipoprotein cholesterol to a significantly greater extent than atorvastatin 10 mg/day, pravastatin 20 mg/day, and simvastatin 20 mg/day. In addition, rosuvastatin exhibited beneficial effects on other lipid parameters such as high-density lipoprotein cholesterol and triglycerides. Rosuvastatin's safety profile was demonstrated to be similar to those of other statins. Given its favorable pharmacokinetic and pharmacodynamic characteristics, rosuvastatin is likely to become a valuable addition to the statin drug class. The author reviews the pharmacologic and pharmacokinetic properties of this new statin.

Original languageEnglish (US)
Pages (from-to)72-78
Number of pages7
JournalHeart Disease
Volume5
Issue number1
StatePublished - Jan 2003

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coenzyme A
Hypercholesterolemia
Oxidoreductases
Therapeutics
Pharmacokinetics
Lipids
Pravastatin
Simvastatin
Dyslipidemias
Drug Interactions
Pharmaceutical Preparations
LDL Cholesterol
Cytochrome P-450 Enzyme System
HDL Cholesterol
Rosuvastatin Calcium
Hepatocytes
Clinical Trials
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rosuvastatin : A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. / Cheng-Lai, Angela.

In: Heart Disease, Vol. 5, No. 1, 01.2003, p. 72-78.

Research output: Contribution to journalArticle

@article{69d7cf285efe471b984b4cacdc5a65a6,
title = "Rosuvastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia",
abstract = "Because of their excellent tolerability and their positive impact on lipid parameters, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have become the drugs of first choice for many patients with dyslipidemia. Rosuvastatin is an investigational statin in the U.S. with a number of favorable characteristics, which include low lipophilicity, high hepatocyte selectivity, minimal metabolism, and a low propensity for cytochrome P450 drug interactions. Rosuvastatin has been studied at doses ranging from 1 to 80 mg. In comparative clinical trials, rosuvastatin given at 5 to 10 mg/day reduced low-density lipoprotein cholesterol to a significantly greater extent than atorvastatin 10 mg/day, pravastatin 20 mg/day, and simvastatin 20 mg/day. In addition, rosuvastatin exhibited beneficial effects on other lipid parameters such as high-density lipoprotein cholesterol and triglycerides. Rosuvastatin's safety profile was demonstrated to be similar to those of other statins. Given its favorable pharmacokinetic and pharmacodynamic characteristics, rosuvastatin is likely to become a valuable addition to the statin drug class. The author reviews the pharmacologic and pharmacokinetic properties of this new statin.",
author = "Angela Cheng-Lai",
year = "2003",
month = "1",
language = "English (US)",
volume = "5",
pages = "72--78",
journal = "Heart Disease",
issn = "1521-737X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Rosuvastatin

T2 - A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

AU - Cheng-Lai, Angela

PY - 2003/1

Y1 - 2003/1

N2 - Because of their excellent tolerability and their positive impact on lipid parameters, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have become the drugs of first choice for many patients with dyslipidemia. Rosuvastatin is an investigational statin in the U.S. with a number of favorable characteristics, which include low lipophilicity, high hepatocyte selectivity, minimal metabolism, and a low propensity for cytochrome P450 drug interactions. Rosuvastatin has been studied at doses ranging from 1 to 80 mg. In comparative clinical trials, rosuvastatin given at 5 to 10 mg/day reduced low-density lipoprotein cholesterol to a significantly greater extent than atorvastatin 10 mg/day, pravastatin 20 mg/day, and simvastatin 20 mg/day. In addition, rosuvastatin exhibited beneficial effects on other lipid parameters such as high-density lipoprotein cholesterol and triglycerides. Rosuvastatin's safety profile was demonstrated to be similar to those of other statins. Given its favorable pharmacokinetic and pharmacodynamic characteristics, rosuvastatin is likely to become a valuable addition to the statin drug class. The author reviews the pharmacologic and pharmacokinetic properties of this new statin.

AB - Because of their excellent tolerability and their positive impact on lipid parameters, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have become the drugs of first choice for many patients with dyslipidemia. Rosuvastatin is an investigational statin in the U.S. with a number of favorable characteristics, which include low lipophilicity, high hepatocyte selectivity, minimal metabolism, and a low propensity for cytochrome P450 drug interactions. Rosuvastatin has been studied at doses ranging from 1 to 80 mg. In comparative clinical trials, rosuvastatin given at 5 to 10 mg/day reduced low-density lipoprotein cholesterol to a significantly greater extent than atorvastatin 10 mg/day, pravastatin 20 mg/day, and simvastatin 20 mg/day. In addition, rosuvastatin exhibited beneficial effects on other lipid parameters such as high-density lipoprotein cholesterol and triglycerides. Rosuvastatin's safety profile was demonstrated to be similar to those of other statins. Given its favorable pharmacokinetic and pharmacodynamic characteristics, rosuvastatin is likely to become a valuable addition to the statin drug class. The author reviews the pharmacologic and pharmacokinetic properties of this new statin.

UR - http://www.scopus.com/inward/record.url?scp=0037262222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037262222&partnerID=8YFLogxK

M3 - Article

C2 - 12549990

AN - SCOPUS:0037262222

VL - 5

SP - 72

EP - 78

JO - Heart Disease

JF - Heart Disease

SN - 1521-737X

IS - 1

ER -